ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on August 3, 2007

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on August 3, 2007
    SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, today announced that it intends to
report the Company's second quarter 2007 financial results via press
release after the financial markets close on Friday, August 3, 2007.
Following the announcement, Evan M. Levine, Chief Executive Officer, and
Gregory P. Hanson, Senior Vice President and Chief Financial Officer, are
scheduled to host a conference call and webcast discussion of the results
and provide a general corporate update. Other members of ADVENTRX's
executive management team will also be available to take investor
questions. Access to the event can be obtained as follows:
    Live access on Friday, August 3, 2007, 1:30 p.m. Pacific Time / 4:30
p.m. Eastern Time:
   -- Telephone (877) 704-5384 (domestic) or (913) 312-1297 (international)

   -- The webcast will be available live by accessing ADVENTRX's website at
      http://www.adventrx.com under "Investors"


    Replay access:

    -- Telephone replay will be available through September 3, 2007 by dialing
      (888) 203-1112 and entering the passcode 7724051

    -- Replays of the webcast will be available through September 3, 2007 by
       accessing ADVENTRX's website at http://www.adventrx.com under
       "Investors"
    About ADVENTRX Pharmaceuticals
    ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. The Company's
lead product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b
clinical trials for the treatment of metastatic colorectal cancer, as well
as in a Phase 2 clinical trial for the treatment of advanced breast cancer.
More information can be found on ADVENTRX's web site at
http://www.adventrx.com.
    Forward Looking Statement
    ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These potential risks and uncertainties
include, but are not limited to: the risk that ADVENTRX will be unable to
raise sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the potential to attract a
strategic partner and the terms of any related transaction; the ability to
timely enroll subjects in ADVENTRX's current and anticipated clinical
trials; the potential for CoFactor and ADVENTRX's other product candidates
to receive regulatory approval for one or more indications on a timely
basis or at all, and the uncertain process of seeking regulatory approval;
other difficulties or delays in developing, testing, manufacturing and
marketing of and obtaining regulatory approval for CoFactor or ADVENTRX's
other product candidates; the potential for regulatory authorities to
require additional preclinical work or other clinical requirements to
support regulatory filings; the scope and validity of patent protection for
CoFactor and ADVENTRX's other product candidates; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov.
    ADVENTRX assumes no obligation to revise or update any forward-looking
statement, including as set forth in this press release, to reflect events
or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
http://www.adventrx.com
http://www.prnewswire.com/comp/920134.html /
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
Inc., +1-858-552-0866